Terremoto Biosciences
Selective AKT1 protein kinase inhibitors for cancer and genetic vascular disorders
- Sector
- Biotech
- Founded
- 2022
- Latest Form D
- $40.7M, Apr 2026
- Total capital
- $40.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $40.7M
- 1 Form D · last Apr 2026
- 6 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 27 pending · first 2026
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$40.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Charles BaumExecutive Officer, DirectorNamed in SEC Form D filings
- Daniel O'ConnellDirectorNamed in SEC Form D filings
- Grace LuExecutive OfficerNamed in SEC Form D filings
- James ChristensenExecutive Officer, DirectorNamed in SEC Form D filings
- Michael GollerDirectorNamed in SEC Form D filings
- Peter ThompsonDirectorNamed in SEC Form D filings
Show all 7 people
- Reid HuberDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 29- PendingCysteine Covalent Modifiers Of AKT1 And Uses ThereofUSPTOApplication 19441528
- GrantedNon-covalent Modifiers Of AKT1 And Uses ThereofUSPTOUS 12,624,034
- GrantedCysteine Covalent Modifiers Of AKT1 And Uses ThereofUSPTOUS 12,570,655
Show all 29 patent records
- Cysteine Covalent Modifiers Of AKT1 And Uses ThereofSep 3, 2026 · Application 19441528Pending
- Non-covalent Modifiers Of AKT1 And Uses ThereofMay 12, 2026 · US 12,624,034Granted
- Cysteine Covalent Modifiers Of AKT1 And Uses ThereofMar 10, 2026 · US 12,570,655Granted
- Covalent Modifiers Of AKT1 And Uses ThereofFeb 26, 2026 · Application 19305122Pending
- Reversible Lysine Covalent Modifiers Of CDK2 And Uses ThereofSep 18, 2025 · Application 19222770Pending
- Reversible Lysine Covalent Modifiers Of Egfr And Uses ThereofDec 12, 2024 · Application 18640370Pending
- Cysteine Covalent Modifiers Of AKT1 And Uses ThereofApplication 63686523Pending
- Non-covalent Modifiers Of AKT1 And Uses ThereofApplication PCTUS2024040866Pending
- Reversible Lysine Covalent Modifiers Of CDK2 And Uses ThereofApplication 63674639Pending
- Non-covalent Modifiers Of AKT1 And Uses ThereofApplication 63650658Pending
- Cysteine Covalent Modifiers Of AKT1 And Uses ThereofApplication 63632216Pending
- Cysteine Covalent Modifiers Of AKT1 And Uses ThereofApplication 63632217Pending
- Cysteine Covalent Modifiers Of AKT1 And Uses ThereofApplication 63562578Pending
- Covalent Modifiers Of AKT1 And Uses ThereofApplication PCTUS2024017162Pending
- Covalent Modifiers Of AKT1 And Uses ThereofApplication 63618164Pending
- Reversible Lysine Covalent Modifiers Of CDK2 And Uses ThereofApplication 63545413Pending
- Cysteine Covalent Modifiers Of AKT1 And Uses ThereofApplication 63590256Pending
- Non-covalent Modifiers Of AKT1 And Uses ThereofApplication 63517760Pending
- Covalent Modifiers Of AKT1 And Uses ThereofApplication 63506224Pending
- Covalent Modifiers Of AKT1 And Uses ThereofApplication PCTUS2023063513Pending
- Covalent Modifiers Of AKT1 And Uses ThereofApplication 63486884Pending
- Reversible Lysine Covalent Modifiers Of Egfr And Uses ThereofApplication PCTUS2022078557Pending
- Reversible Lysine Covalent Modifiers Of Egfr And Uses ThereofApplication 63370997Pending
- Reversible Lysine Covalent Modifiers Of Egfr And Uses ThereofApplication 63270988Pending
- Cysteine Covalent Modifiers Of AKT1 And Uses ThereofApplication PCTUS2025023965Pending
- Cysteine Covalent Modifiers Of AKT1 And Uses ThereofApplication PCTUS2025023954Pending
- Cysteine Covalent Modifiers Of AKT1 And Uses ThereofApplication 63716968Pending
- Reversible Lysine Covalent Modifiers Of CDK2 And Uses ThereofApplication PCTUS2024052642Pending
- Cysteine Covalent Modifiers Of AKT1 And Uses ThereofApplication PCTUS2024051051Pending
Related companies, and why
- AdimabSimilar federal contract value in Biotech · null in contracts
- AvitideSimilar federal contract value in Biotech · null in contracts
- NEXGENIA, INC.Similar federal contract value in Biotech · null in contracts
- NephroDI Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Cerebral TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Lindy Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .